ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 001A03

Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension

Identifieur interne : 001A03 ( PascalFrancis/Corpus ); précédent : 001A02; suivant : 001A04

Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension

Auteurs : J. M. Senard ; O. Rascol ; A. Rascol ; J. L. Montastruc

Source :

Fundamental and clinical pharmacology [ 0767-3981 ] ; 1993.

RBID : Pascal:94-0009214

Descripteurs français

Pascal (Inist)
- Yohimbine, Bloquant α-adrénergique, Récepteur α2-adrénergique, Parkinson maladie, Complication, Hypotension artérielle orthostatique, Ambulatoire, Pression artérielle, Homme, Hémodynamique, Chimiothérapie, Traitement.

English descriptors

KwdEn :
- Alpha blocking agent, Ambulatory, Arterial pressure, Chemotherapy, Complication, Hemodynamics, Human, Parkinson disease, Postural hypotension, Treatment, Yohimbine, α2-Adrenergic receptor.

Abstract

Yohimbine is an alpha-adrenergic antagonist which has been proposed for the treatment of orthostatic hypotension (OH). We investigated in a double-blind placebo-controlled crossover trial the effects of yohimbine (2 mg tid) on blood pressure (BP) and heart rate (HR) using ambulatory monitoring of blood pressure (AMBP) in 17 patients (69±5 years) with Parkinson's disease (PD) suffering from non drug-induced OH. At the end of each sequence of 4 weeks, mean systolic (SBP) and diastolic (DBP) BP and HR (±SD), BP variability (coefficient of variation of the mean) and nychtemeral rhythm were calculated for day-time (09 00-19 00 h) and night-time (23 00-06 00 h)

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0767-3981`
A02	`01`			`@0 FCPHEZ`
A03		`1`		`@0 Fundam. clin. pharmacol.`
A05				`@2 7`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension`
A11	`01`	`1`		`@1 SENARD (J. M.)`
A11	`02`	`1`		`@1 RASCOL (O.)`
A11	`03`	`1`		`@1 RASCOL (A.)`
A11	`04`	`1`		`@1 MONTASTRUC (J. L.)`
A14	`01`			`@1 INSERM Fac. médecine, lab. pharmacologie médicale clin. @2 31073 Toulouse @3 FRA @Z 1 aut. @Z 2 aut. @Z 4 aut.`
A14	`02`			`@1 Hôp. Purpan, serv. neurologie @2 31059 Toulouse @3 FRA @Z 1 aut. @Z 2 aut. @Z 4 aut.`
A20				`@1 465-470`
A21				`@1 1993`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 14711 @5 354000048284230080`
A44				`@0 0000`
A45				`@0 1 p.`
A47	`01`	`1`		`@0 94-0009214`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Fundamental and clinical pharmacology`
A66	`01`			`@0 FRA`
C01	`01`		`ENG`	@0 Yohimbine is an alpha-adrenergic antagonist which has been proposed for the treatment of orthostatic hypotension (OH). We investigated in a double-blind placebo-controlled crossover trial the effects of yohimbine (2 mg tid) on blood pressure (BP) and heart rate (HR) using ambulatory monitoring of blood pressure (AMBP) in 17 patients (69±5 years) with Parkinson's disease (PD) suffering from non drug-induced OH. At the end of each sequence of 4 weeks, mean systolic (SBP) and diastolic (DBP) BP and HR (±SD), BP variability (coefficient of variation of the mean) and nychtemeral rhythm were calculated for day-time (09 00-19 00 h) and night-time (23 00-06 00 h)
C02	`01`	`X`		`@0 002B02F09`
C03	`01`	`X`	`FRE`	`@0 Yohimbine @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Yohimbine @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Bloquant α-adrénergique @5 04`
C03	`02`	`X`	`ENG`	`@0 Alpha blocking agent @5 04`
C03	`02`	`X`	`SPA`	`@0 Bloqueador α-adrenérgico @5 04`
C03	`03`	`X`	`FRE`	`@0 Récepteur α2-adrénergique @5 07`
C03	`03`	`X`	`ENG`	`@0 α2-Adrenergic receptor @5 07 @6 «α2-»Adrenergic receptor`
C03	`03`	`X`	`SPA`	`@0 Receptor α2-adrenérgico @5 07`
C03	`04`	`X`	`FRE`	`@0 Parkinson maladie @2 NM @5 10`
C03	`04`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 10`
C03	`04`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 10`
C03	`05`	`X`	`FRE`	`@0 Complication @5 11`
C03	`05`	`X`	`ENG`	`@0 Complication @5 11`
C03	`05`	`X`	`SPA`	`@0 Complicación @5 11`
C03	`06`	`X`	`FRE`	`@0 Hypotension artérielle orthostatique @2 NM @5 13`
C03	`06`	`X`	`ENG`	`@0 Postural hypotension @2 NM @5 13`
C03	`06`	`X`	`SPA`	`@0 Hipotensión arterial ortostática @2 NM @5 13`
C03	`07`	`X`	`FRE`	`@0 Ambulatoire @5 16`
C03	`07`	`X`	`ENG`	`@0 Ambulatory @5 16`
C03	`07`	`X`	`SPA`	`@0 Ambulatorio @5 16`
C03	`08`	`X`	`FRE`	`@0 Pression artérielle @5 17`
C03	`08`	`X`	`ENG`	`@0 Arterial pressure @5 17`
C03	`08`	`X`	`SPA`	`@0 Presión arterial @5 17`
C03	`09`	`X`	`FRE`	`@0 Homme @5 18`
C03	`09`	`X`	`ENG`	`@0 Human @5 18`
C03	`09`	`X`	`SPA`	`@0 Hombre @5 18`
C03	`10`	`X`	`FRE`	`@0 Hémodynamique @5 19`
C03	`10`	`X`	`ENG`	`@0 Hemodynamics @5 19`
C03	`10`	`X`	`SPA`	`@0 Hemodinámica @5 19`
C03	`11`	`X`	`FRE`	`@0 Chimiothérapie @5 20`
C03	`11`	`X`	`ENG`	`@0 Chemotherapy @5 20`
C03	`11`	`X`	`SPA`	`@0 Quimioterapia @5 20`
C03	`12`	`X`	`FRE`	`@0 Traitement @5 21`
C03	`12`	`X`	`ENG`	`@0 Treatment @5 21`
C03	`12`	`X`	`GER`	`@0 Aufbereiten @5 21`
C03	`12`	`X`	`SPA`	`@0 Tratamiento @5 21`
C07	`01`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 62`
C07	`01`	`X`	`ENG`	`@0 Central nervous system disease @5 62`
C07	`01`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 62`
C07	`02`	`X`	`FRE`	`@0 Encéphale pathologie @5 63`
C07	`02`	`X`	`ENG`	`@0 Cerebral disorder @5 63`
C07	`02`	`X`	`SPA`	`@0 Encéfalo patología @5 63`
C07	`03`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 64`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 64`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 64`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 65`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 65`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 65`
C07	`05`	`X`	`FRE`	`@0 Appareil circulatoire pathologie @4 INC @5 69`
C07	`06`	`X`	`FRE`	`@0 Système nerveux pathologie @4 INC @5 70`
C07	`07`	`X`	`FRE`	`@0 Système nerveux autonome pathologie @4 INC @5 71`
N21				`@1 006`

Format Inist (serveur)

NO :	PASCAL 94-0009214 INIST
ET :	Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension
AU :	SENARD (J. M.); RASCOL (O.); RASCOL (A.); MONTASTRUC (J. L.)
AF :	INSERM Fac. médecine, lab. pharmacologie médicale clin./31073 Toulouse/France (1 aut., 2 aut., 4 aut.); Hôp. Purpan, serv. neurologie/31059 Toulouse/France (1 aut., 2 aut., 4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Fundamental and clinical pharmacology; ISSN 0767-3981; Coden FCPHEZ; France; Da. 1993; Vol. 7; No. 8; Pp. 465-470; Bibl. 1 p.
LA :	Anglais
EA :	Yohimbine is an alpha-adrenergic antagonist which has been proposed for the treatment of orthostatic hypotension (OH). We investigated in a double-blind placebo-controlled crossover trial the effects of yohimbine (2 mg tid) on blood pressure (BP) and heart rate (HR) using ambulatory monitoring of blood pressure (AMBP) in 17 patients (69±5 years) with Parkinson's disease (PD) suffering from non drug-induced OH. At the end of each sequence of 4 weeks, mean systolic (SBP) and diastolic (DBP) BP and HR (±SD), BP variability (coefficient of variation of the mean) and nychtemeral rhythm were calculated for day-time (09 00-19 00 h) and night-time (23 00-06 00 h)
CC :	002B02F09
FD :	Yohimbine; Bloquant α-adrénergique; Récepteur α2-adrénergique; Parkinson maladie; Complication; Hypotension artérielle orthostatique; Ambulatoire; Pression artérielle; Homme; Hémodynamique; Chimiothérapie; Traitement
FG :	Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Appareil circulatoire pathologie; Système nerveux pathologie; Système nerveux autonome pathologie
ED :	Yohimbine; Alpha blocking agent; α2-Adrenergic receptor; Parkinson disease; Complication; Postural hypotension; Ambulatory; Arterial pressure; Human; Hemodynamics; Chemotherapy; Treatment
EG :	Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
GD :	Aufbereiten
SD :	Bloqueador α-adrenérgico; Receptor α2-adrenérgico; Parkinson enfermedad; Complicación; Hipotensión arterial ortostática; Ambulatorio; Presión arterial; Hombre; Hemodinámica; Quimioterapia; Tratamiento
LO :	INIST-14711.354000048284230080
ID :	94-0009214

Links to Exploration step

Pascal:94-0009214

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension</title>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM Fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Hôp. Purpan, serv. neurologie</s1>
<s2>31059 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM Fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Hôp. Purpan, serv. neurologie</s1>
<s2>31059 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM Fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Hôp. Purpan, serv. neurologie</s1>
<s2>31059 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">94-0009214</idno>
<date when="1993">1993</date>
<idno type="stanalyst">PASCAL 94-0009214 INIST</idno>
<idno type="RBID">Pascal:94-0009214</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A03</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension</title>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM Fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Hôp. Purpan, serv. neurologie</s1>
<s2>31059 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM Fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Hôp. Purpan, serv. neurologie</s1>
<s2>31059 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM Fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Hôp. Purpan, serv. neurologie</s1>
<s2>31059 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Fundamental and clinical pharmacology</title>
<title level="j" type="abbreviated">Fundam. clin. pharmacol.</title>
<idno type="ISSN">0767-3981</idno>
<imprint><date when="1993">1993</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Fundamental and clinical pharmacology</title>
<title level="j" type="abbreviated">Fundam. clin. pharmacol.</title>
<idno type="ISSN">0767-3981</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alpha blocking agent</term>
<term>Ambulatory</term>
<term>Arterial pressure</term>
<term>Chemotherapy</term>
<term>Complication</term>
<term>Hemodynamics</term>
<term>Human</term>
<term>Parkinson disease</term>
<term>Postural hypotension</term>
<term>Treatment</term>
<term>Yohimbine</term>
<term>α2-Adrenergic receptor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Yohimbine</term>
<term>Bloquant α-adrénergique</term>
<term>Récepteur α2-adrénergique</term>
<term>Parkinson maladie</term>
<term>Complication</term>
<term>Hypotension artérielle orthostatique</term>
<term>Ambulatoire</term>
<term>Pression artérielle</term>
<term>Homme</term>
<term>Hémodynamique</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Yohimbine is an alpha-adrenergic antagonist which has been proposed for the treatment of orthostatic hypotension (OH). We investigated in a double-blind placebo-controlled crossover trial the effects of yohimbine (2 mg tid) on blood pressure (BP) and heart rate (HR) using ambulatory monitoring of blood pressure (AMBP) in 17 patients (69±5 years) with Parkinson's disease (PD) suffering from non drug-induced OH. At the end of each sequence of 4 weeks, mean systolic (SBP) and diastolic (DBP) BP and HR (±SD), BP variability (coefficient of variation of the mean) and nychtemeral rhythm were calculated for day-time (09 00-19 00 h) and night-time (23 00-06 00 h)</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0767-3981</s0>
</fA01>
<fA02 i1="01"><s0>FCPHEZ</s0>
</fA02>
<fA03 i2="1"><s0>Fundam. clin. pharmacol.</s0>
</fA03>
<fA05><s2>7</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SENARD (J. M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>RASCOL (O.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>RASCOL (A.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MONTASTRUC (J. L.)</s1>
</fA11>
<fA14 i1="01"><s1>INSERM Fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Hôp. Purpan, serv. neurologie</s1>
<s2>31059 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>465-470</s1>
</fA20>
<fA21><s1>1993</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>14711</s2>
<s5>354000048284230080</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>1 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>94-0009214</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Fundamental and clinical pharmacology</s0>
</fA64>
<fA66 i1="01"><s0>FRA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Yohimbine is an alpha-adrenergic antagonist which has been proposed for the treatment of orthostatic hypotension (OH). We investigated in a double-blind placebo-controlled crossover trial the effects of yohimbine (2 mg tid) on blood pressure (BP) and heart rate (HR) using ambulatory monitoring of blood pressure (AMBP) in 17 patients (69±5 years) with Parkinson's disease (PD) suffering from non drug-induced OH. At the end of each sequence of 4 weeks, mean systolic (SBP) and diastolic (DBP) BP and HR (±SD), BP variability (coefficient of variation of the mean) and nychtemeral rhythm were calculated for day-time (09 00-19 00 h) and night-time (23 00-06 00 h)</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02F09</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Yohimbine</s0>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Yohimbine</s0>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Bloquant α-adrénergique</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Alpha blocking agent</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Bloqueador α-adrenérgico</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Récepteur α2-adrénergique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>α2-Adrenergic receptor</s0>
<s5>07</s5>
<s6>«α2-»Adrenergic receptor</s6>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Receptor α2-adrenérgico</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Complication</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Complication</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Complicación</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Hypotension artérielle orthostatique</s0>
<s2>NM</s2>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Postural hypotension</s0>
<s2>NM</s2>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hipotensión arterial ortostática</s0>
<s2>NM</s2>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Ambulatoire</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Ambulatory</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Ambulatorio</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Pression artérielle</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Arterial pressure</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Presión arterial</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Hémodynamique</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Hemodynamics</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hemodinámica</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Traitement</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Treatment</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>21</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>62</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>62</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>62</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>63</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>63</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>63</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>64</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>64</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>64</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>65</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>65</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>65</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0>
<s4>INC</s4>
<s5>69</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s4>INC</s4>
<s5>70</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Système nerveux autonome pathologie</s0>
<s4>INC</s4>
<s5>71</s5>
</fC07>
<fN21><s1>006</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 94-0009214 INIST</NO>
<ET>Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension</ET>
<AU>SENARD (J. M.); RASCOL (O.); RASCOL (A.); MONTASTRUC (J. L.)</AU>
<AF>INSERM Fac. médecine, lab. pharmacologie médicale clin./31073 Toulouse/France (1 aut., 2 aut., 4 aut.); Hôp. Purpan, serv. neurologie/31059 Toulouse/France (1 aut., 2 aut., 4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Fundamental and clinical pharmacology; ISSN 0767-3981; Coden FCPHEZ; France; Da. 1993; Vol. 7; No. 8; Pp. 465-470; Bibl. 1 p.</SO>
<LA>Anglais</LA>
<EA>Yohimbine is an alpha-adrenergic antagonist which has been proposed for the treatment of orthostatic hypotension (OH). We investigated in a double-blind placebo-controlled crossover trial the effects of yohimbine (2 mg tid) on blood pressure (BP) and heart rate (HR) using ambulatory monitoring of blood pressure (AMBP) in 17 patients (69±5 years) with Parkinson's disease (PD) suffering from non drug-induced OH. At the end of each sequence of 4 weeks, mean systolic (SBP) and diastolic (DBP) BP and HR (±SD), BP variability (coefficient of variation of the mean) and nychtemeral rhythm were calculated for day-time (09 00-19 00 h) and night-time (23 00-06 00 h)</EA>
<CC>002B02F09</CC>
<FD>Yohimbine; Bloquant α-adrénergique; Récepteur α2-adrénergique; Parkinson maladie; Complication; Hypotension artérielle orthostatique; Ambulatoire; Pression artérielle; Homme; Hémodynamique; Chimiothérapie; Traitement</FD>
<FG>Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Appareil circulatoire pathologie; Système nerveux pathologie; Système nerveux autonome pathologie</FG>
<ED>Yohimbine; Alpha blocking agent; α2-Adrenergic receptor; Parkinson disease; Complication; Postural hypotension; Ambulatory; Arterial pressure; Human; Hemodynamics; Chemotherapy; Treatment</ED>
<EG>Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<GD>Aufbereiten</GD>
<SD>Bloqueador α-adrenérgico; Receptor α2-adrenérgico; Parkinson enfermedad; Complicación; Hipotensión arterial ortostática; Ambulatorio; Presión arterial; Hombre; Hemodinámica; Quimioterapia; Tratamiento</SD>
<LO>INIST-14711.354000048284230080</LO>
<ID>94-0009214</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A03 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001A03 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:94-0009214
   |texte=   Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension

Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri